CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
利用单细胞测序技术解析并推进 CAR-T 细胞治疗
英文原题：Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies.
查看英文原题
Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞疗法在癌症免疫治疗中取得了显著进展，但若干机制不明的挑战阻碍了其广泛的临床应用。单细胞测序技术以前所未有的分辨率对细胞异质性和分子模式进行强大的无偏分析，极大地促进了我们对免疫学和肿瘤学的理解。在这篇综述中，我们总结了单细胞测序技术在CAR-T 细胞治疗中的最新应用，包括生物学特征、临床反应和不良事件的最新机制、有助于CAR-T 细胞治疗发展的有前景的策略以及CAR靶点选择。总体而言，我们提出了一种多组学研究模式，以指导CAR-T 细胞治疗潜在的未来研究。
展开英文摘要原文
Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical application. Single-cell sequencing technologies, with the powerful unbiased analysis of cellular heterogeneity and molecular patterns at unprecedented resolution, have greatly advanced our understanding of immunology and oncology.
In this review, we summarize the recent applications of single-cell sequencing technologies in CAR T-cell therapy, including the biological characteristics, the latest mechanisms of clinical response and adverse events, promising strategies that contribute to the development of CAR T-cell therapy and CAR target selection. Generally, we propose a multi-omics research mode to guide potential future research on CAR T-cell therapy.
论文信息
- 作者
- Huang S、Wang X、Wang Y、Wang Y、Fang C、Wang Y、Chen S、Chen R
- 第一作者单位
- The Second School of Clinical Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou, China.China
- 通讯作者单位
- Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China. liyuhua2011gz@163.com.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Molecular cancer2023 May 6
- 原文标识
- PubMed 37149643 · DOI 10.1186/s12943-023-01783-1
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →